NanoViricides (NNVC) said Tuesday it has raised the financing to support a phase 2 clinical trial of NV-387 oral gummies and is awaiting approval from regulatory agency ACOREP for the drug to treat the current Bundibugyo Ebolavirus in the Democratic Republic of Congo.
NV-387 is the only oral medication under consideration for clinical trial as a treatment of Ebola, NanoViricides said. The drug has excellent stability at room temperature, enabling ease of transport, distribution, and delivery to patient, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments